Replies to post #420368 on Amarin Corp Plc (AMRN)

[Whalatane]

Dusty. Depends how fast they can ramp sales in Spain , and how soon they can bring Italy online.
JMO
Kiwi

[caddiedad]

To Dusty and any other recent newcomer: Read months of previous posts and make sure your BS filter is clean and operational. It’s a steady study as to what’s going on and who is legit vs. misleading. Not sure about how many gp doctors on this site: Optometrist (1)…..

[IgnoranceIsBliss]

Hi Dusty -- there's a wild range of expectations here, created in part by history. A lot of us hold stock that was once as high as $26.

I think if an analyst from Mars landed here and did the math on this company, "it" would look at possible revenue projections and conclude they might peak sales at around $2bn (best case) -- that would translate to net income of around $500mm or so, and after buybacks you might get down to 300mm shares (best case).

So with a P/E of 8 (no, this company doesn't deserve biotech multiples, it's a one-drug company with no pipeline) -- you could conceivably get this thing above $10.

I think $3 to $5 is more realistic -- I would kill for $5.

[couldbebetter]

Dusty18, If all goes well AMRN should hit $3 within a year.
Royalty payments from sales of Vascepa by EddingPharm
should kick in later tis year. Plus, Edding must buy their Vascepa
or the raw material to make it from AMRN. China is a wild-card as
we have no idea as to how Edding will fare in this. Europe is where
the greatest potential value lies for a potential BP BO as exclusivity
there could end up being out to 2039. (That would be very valuable
to a Eurocentric BP acquirer and is what Denner is relying on for a sale
of the company.) Buybacks will not kick in until the third quarter. Until
then, I am hoping that Sarissa and other institutions accumulate shares.
Whatever price Denner has in mind for a BO, the share price should hit
around half that level beforehand...So $6 for a $12 BO (as an example.)

[ziploc_1]

Dusty...This PR from Amarin may shed some lite on the near term future for The near term trejectury for Amarin stock price..

"On January 9, 2024, Amarin entered into a conditional share REPURCHASE agreement with Cantor Fitzgerald & Co. (“Cantor”) to purchase up to $50 million of Amarin’s ordinary shares held in the form of American depository shares (ADSs). The implementation of the share repurchase program will require Amarin shareholder approval as well as UK High Court approval, as required under UK company law. The Company intends to call its 2024 annual general meeting of shareholders early in the second quarter of 2024 to seek shareholder approval of the program, which would be followed by the UK High court process. Amarin anticipates that these steps could be completed by the end of the second quarter of 2024, with share repurchases commencing shortly thereafter."

Assuming that Cantor does not already own these Amarin shares, Cantor will need to buy them in order to sell them to Amarin, as per their repurchase agreement...This should keep the price up, at least until the repurchase agreement is fulfilled...

By that time, catalysts from the US, Europe and ROW, including China, should have begun to check in.